(Q42977805)

English

Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine

scientific article published on 15 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine (English)

1 reference

Europe PubMed Central

12 November 2017

viral persistence

0 references

Japanese encephalitis virus

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

Japanese encephalitis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kamal Desai

1

1 reference

Europe PubMed Central

12 November 2017

L Coudeville

2

1 reference

Europe PubMed Central

12 November 2017

F Bailleux

3

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

15 February 2012

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

30

1 reference

Europe PubMed Central

12 November 2017

15

1 reference

Europe PubMed Central

12 November 2017

2510-2515

1 reference

Europe PubMed Central

12 November 2017

Japanese encephalitis: new options for active immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

New Japanese encephalitis vaccines: alternatives to production in mouse brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

The BUGS project: Evolution, critique and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Bayesian measures of model complexity and fit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Repeated-measures models to evaluate a hepatitis B vaccination programme.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.02.005

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42977805&oldid=1975604126"